Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology

BJU International

Volumn 85, Issue 4, 2000, Pages 392-397

  Keegan, P E ^a   Matthews, J N S ^a   Lunec, J ^a   Neal, D E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; UROLOGY;

HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 0034051499     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00491.x     Document Type: Review

References (19)

1. 1 Keegan PE, Lunec J, Neal DE. p53 and p53-regulated genes in bladder cancer. Br J Urol 1998; 82: 710-20
2. 2 Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Prac 1997; 193: 767-75
3. 3 Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997; 79: 367-72
4. 4 Hofmockel G, Bassukas ID, Wittmann A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 1997; 80: 11-7
5. 5 Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treatment 1992; 22: 197-206
6. 6 Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35
7. 7 Lausen B, Schumacher M. Evaluating the effect of optimised cutoff values in the assessment of prognostic factors. Computer Statistics Data Anal 1996; 21: 307-26
8. 8 Hilsenbeck SG, Clark GM. Practical p-value adjustment for optimally selected cutpoints. Statistics Med 1996; 15:103-12
9. 9 Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619-25
10. 10 Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982; 38: 1011-6
11. 11 Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Statistics Med 1996; 15: 2203-13
12. 12 Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics 1992; 48: 73-85
13. 13 Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-6
14. 14 Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 1997; 31: 350-5
15. 15 Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A. p53 expression compared with other prognostic factors in Oms grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol 1997; 32: 229-36
16. 16 Cronin KJ, Williams NN, Kerin MJ et al. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J Urol 1994; 152: 834-6
17. 17 Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996; 155: 858-62
18. 18 Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997; 157: 219-22
19. 19 Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Urology 1996; 47: 218-24